opdivo
BMS’ Opdivo+Yervoy combo fails in small cell lung cancer
November 27, 2018Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …
Azacitidine and nivolumab combo proves successful in phase II trial
November 13, 2018Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …
BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients
October 22, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo
American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …
BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy
September 10, 2018Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma
Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …
FDA approves Bristol Myers Squibb’s Opdivo in small-cell lung cancer
August 20, 2018Sales and Marketing Bristol-Myers Squibb, FDA, approval, bristol myers squibb, lung cancer, opdivo
The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) for patients with metastatic small-cell lung cancer (SCLC), as the first …
NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma
July 5, 2018Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma
Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …
The July/August issue of Pharmafocus is now live!
July 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Elizabeth Holmes, NHS, Sanofi, Theranos, UK, ambien, manufacturing compliance, opdivo, patient recruitment, patient retention, pharma
The new July/August edition of Pharmafocus is now available to read online.
BMS’ Opdivo becomes first immuno-oncology agent available in China
June 18, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …
BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
May 2, 2018Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3
Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …
The May 2018 issue of Pharmafocus is now live!
April 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax
Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …
BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer
April 18, 2018Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma
The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …
Japan saves record $12.2bn in 2017 through greater generic use
March 7, 2018Research and Development, Sales and Marketing Japan, generics, keytruda, opdivo, pharma
Through a concerted shift from branded drugs to generic equivalents as a means to lower prescription costs, Japan is estimated …
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression
February 6, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …
BMS partners again with the company behind Opdivo
December 14, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to …
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer
October 13, 2017Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical
Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …
Latest content
